*All times listed are Central European Time (CET)
8:30 am Morning Coffee
9:15 am Opening Remarks
Novel Tracer Technology
9:30 am In Vivo Click Strategies for Antibody-Based Imaging and Radiotherapy
Synopsis
- Radioimmunoimaging and -therapy is hampered by low target-blood ratios
- We will present strategies that use the in vivo click reaction between tetrazine with trans-cyclooctene-modified mAbs to boost this ratio with temporal control and broad applicability
10:00 am Unlocking the Potential of Theranostics
Synopsis
10:10 am Morning Refreshment Break
Case Studies Targeting HER-2 – Tracing and Treating
11:00 am Affibody Tracers – Approach to Truly Personalize Medicine In HER-2 Cancer
Synopsis
- Advantages of Affibody tracers as demonstrated in a 40-patient Phase II study in Breast Cancer patients
- Impact of Affibody PET-Imaging on personalized treatment decisions for potentially HER2 positive tumors
- Future potential in molecular imaging and as targeted radiopharmaceuticals
11:30 am CAM-H2 – New Treatment Option In HER2- Positive Cancer
Synopsis
- Building on strengths of single domain antibody-based platform
- Evolving landscape in HER2-positive cancer
- Ongoing CAM-H2 Phase I/II clinical study
Combination & Personalised Therapy in RLT
12:00 pm Personalized Medicine from A Nucmed Perspective
Synopsis
- Optimizing response rates through careful patient stratification
- Improving outcomes by utilizing imaging
- Applying learnings from personalised medicine in other areas of oncology
12:30 pm Radiobiology Of Radionuclide Therapy: Using Molecular Insights to Improve Treatment Outcome For Cancer Patients
Synopsis
- What is radiobiology and why is it important to understand these underlying mechanisms when designing new or more optimal radionuclide therapy strategies?
- Insight into different radiobiological parameters of alpha and beta radionuclide therapy.
- Example of improvement of radionuclide therapy using combination therapies therapies.
Novel Tracer & Targeting Technology
11:00 am Successful Real-Time In Vivo Imaging of Pb-212 and Ac-225 in Preclinical Oncological Models
Synopsis
- Phase 1 Development & Global Perspectives of Regulation
- Challenges in imaging Pb-212 and Ac-225 with current preclinical and clinical SPECT systems
- Optimization of BIOEMTECH “eyes” for efficient imaging of Pb-212 and Ac-225
- In vivo mouse imaging of low activity Pb-212 and Ac-225 labelled compounds
- Added value of preclinical imaging over standard ex-vivo biodistribution studies
11:15 am FAPI Imaging in Selecting Theranostics
Synopsis
- Novel FAPI radiotracer 1st in human biodistribution study for improved understanding of the dynamics of FAPI targeting
- Tumor: background uptake
- Pitfalls in interpretation
11:45 am Affilin®-Based Next-Generation Targeted Radiopharmaceuticals
Synopsis
- Novel target binding proteins called Affilin® ligands
- Precision Targeting Toolbox that leverages the high engineerability of the Affilin® ligands to custom design next-generation Affilin®-Radiotheranostics, and
- The proprietary HEADs technology to fine-tune the half-life and pharmacokinetics of Affilin® radio conjugates for therapy and imaging.
12:00 pm The Case For and Against Companion Diagnostic Tracers
Synopsis
- Why we should have imaging companion tracers
- Why we should not have them
- How to think about ways out of the dilemma
12:30 pm Diagnostic Radioimmunocionjugate Targeting the Oxidized Macrophage Migration Inhibitory Factor (oxMIF)
Synopsis
- Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine consisting of three identical
subunits that drives tumorigenic cell signaling and exerts immunomodulatory activities in the tumor microenvironment - ON102 is a radioimmunoconjugate designed to provide a
non-invasive approach for diagnostic applications
1:00 pm Networking Lunch
Commercialising & Financing Targeted Radiopharmaceuticals
1:45 pm Funding Challenges and Considerations for Radiopharmaceuticals
2:15 pm Panel Discussion: Discuss the Key Stages of a Roll Out and How Each Stakeholder & Specialist Can Contribute for Assured Success
Synopsis
- Outline how we can prevent a “copy and paste” approach to commercialization strategies, particularly through looking at the lessons learnt from the launches of Bexxar and Zevalin
- Explore how each role can maximise their input into the launch plan
- Identify the most common potholes that companies fall into when launching any pharmaceutical product
2:45 pm IAEA Activities: Efforts Towards Global Sustainable Developments in Radiopharmaceuticals
Synopsis
- The IAEA co-ordinated research projects current and concluded in recent pasts and their impact on radiopharmaceutical developments
- Technical support for capacity building in developing Member States in radioisotope production and radiopharmaceutical area
- Related IAEA publications, databases, conferences